Treatments and survival in high-grade osteosarcoma
Part of Cancer clinical trials.
This study looks back at the treatments people received for high-grade osteosarcoma and how long they lived or stayed cancer-free. It aims to understand which treatments are linked to better outcomes, which could help guide future care decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with high-grade osteosarcoma (a type of bone cancer).
- You were 12 years old or older when diagnosed.
- You finished your first round of treatment by June 30, 2021.
- You have follow-up information for at least 12 months after diagnosis, or you had an event like relapse, spread, or death within 12 months.
- You did not have another cancer before osteosarcoma (unless it was minor and fully treated).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study (it mainly watches and records care) for people with high-grade osteosarcoma in an arm or leg. It may help doctors learn which care approaches work best for younger patients with localized disease.
This research study follows young people newly diagnosed with osteosarcoma (a type of bone cancer) who are receiving standard chemotherapy. Researchers will collect information about how the cancer responds to treatment and study biological samples to better understand the disease.
This study is watching people whose high-grade osteosarcoma came back in the same bone area (local relapse) after treatment. It helps doctors understand how local relapse happens, so they can improve future care.
This trial tests removing the tumor with surgery first, then following up with chemotherapy. It's for people with a new, high-grade osteosarcoma in an arm or leg that hasn't spread.
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
This study collects information about people with certain types of bone cancer. By joining, you can help doctors learn more about these rare tumors and improve future treatments.
Hear when a new High-Grade Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.